Souhaitez-vous accéder aux communiqués récents ?

First quarter 2013 revenue rose 23% to EUR 5.9 million (USD 7.8 million) Continuing US investments in both FDA regulatory process and US operations Great momentum and success achieved at...

Four Scientific Sessions Highlighted HIFU for Treatment of Prostate Cancer HIFU Featured in Plenary Lecture and Two Moderated Posters at Engineering and Urology Society Meeting Significant...

LYON, France, May 13, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its first quarter 2013 results announcement,...

Four scientific sessions highlighting HIFU outcomes for treatment of prostate cancer One AUA accepted poster presentation highlighting Sonolith lithotripter and its exclusive ultrasound Visio...

First quarter total revenue of approximately EUR 5.9 million (USD 7.8 million), up 23% year-over-year Ten lithotripsy devices sold in first quarter 2013 Received FDA acceptance for PMA...

Highlights   Record fourth quarter 2012 revenue of EUR 9.5 million (USD 12.3 million), up 25.3% year-over-year Record full year revenue of EUR 26.1 million (USD 33.6 million), up...

LYON, France, March 28, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the U.S. Food and Drug Administration has provided a...

LYON, France, March 14, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the launch of Focal.One®, its new and innovative robotic...

LYON, France, March 12, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its fourth quarter and full year 2012...

LYON, France, March 7, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the U.S. Food and Drug Administration (FDA) has provided a...